Are New Sleep Apnea Billing Codes Altering The Investment Case For Inspire Medical Systems (INSP)?

• Inspire Medical Systems reported that the AMA CPT Editorial Panel approved new Category I CPT codes that specifically describe its Inspire V sleep apnea system, with these codes scheduled to take effect on January 1, 2028.
• The new Inspire V CPT codes move the therapy into the main procedural coding set, which can influence long term reimbursement clarity and provider workflows once CMS sets valuations.
• We will now look at how Inspire Medical Systems' investment narrative could shift as Inspire V receives dedicated Category I CPT recognition.

Scan what this new CPT path could mean for Inspire Medical Systems, and then compare it with other potential sleep and medtech breakouts on the 35 healthcare AI stocks.

Inspire Medical Systems Investment Narrative Recap

To own Inspire Medical Systems, you need to believe the firm can turn its obstructive sleep apnea franchise and Inspire V rollout into a steady, scalable procedure engine despite recent noise around coding and WISeR related disruption. The AMA approval of Category I CPT codes supports long term clarity, but it does not change that near term execution still hinges on center training, contracting and coding education.

The key near term catalyst remains a visible recovery in implant volumes as reimbursement workflows stabilize and providers get comfortable with Inspire V. The biggest risk is that the slower rollout, legal scrutiny over prior disclosures and any pressure on physician economics linger longer than expected, which could keep revenue growth muted and margins under strain.

The most relevant announcement here is the AMA CPT Editorial Panel decision to create new Category I codes that directly describe Inspire V procedures, effective January 1, 2028. That decision links tightly to earlier expectations that normalization of coding and reimbursement could support steadier procedure revenue and clearer operating margins once temporary disruptions ease.

For you as an investor, the interest is in how those future codes intersect with other reimbursement milestones such as the proposed 2027 Medicare facility payments, which referenced hospital outpatient rates around US$35,414 and ASC rates around US$31,722. The long coding runway gives Inspire Medical Systems time to refine SleepSync, Inspire Connect and Project Horizon so that when the new codes arrive, operational friction from diagnosis to implant has already been reduced.

What The Current Forecasts Assume For Inspire Medical Systems

Inspire Medical Systems' current analyst framework points to revenues of US$991.6 million and earnings of US$74.2 million by 2029. That profile assumes revenue rising at about 3.3% per year and earnings falling by US$60.8 million from US$135.0 million today.

Uncover why Inspire Medical Systems' fair value indicates a 9% potential downside to its current price, leaving little room for error.

Exploring Other Perspectives

Some of the most optimistic analysts looking at Inspire Medical Systems were already leaning hard on the CPT clean up as a key catalyst, assuming about US$1.0b of revenue and US$91.8 million of earnings by 2029. You can now ask whether this new Category I CPT decision nudges those upbeat views even further. Analyst opinions clearly span a wide range, so treat this as one of several possible futures to explore rather than a script the market must follow.

Explore 5 other Inspire Medical Systems fair value estimates, including one that suggests potential upside of as much as 287% from the current price.

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider forming your own view.

• A great starting point for your Inspire Medical Systems research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• See our latest analysis for Inspire Medical Systems. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Inspire Medical Systems' overall financial health at a glance.

Looking For More Ideas Beyond Inspire Medical Systems?

If the Inspire Medical Systems story has sharpened your thinking, it can help to line it up against other potential opportunities using the Simply Wall St Screener. Broaden your watchlist with tools that surface different types of businesses rather than relying on a single theme.

• For investors who care most about balance sheet strength and durability, filter for companies with resilient finances using the list of solid balance sheet and fundamentals (25 results).
• If capital preservation and a smoother ride matter more than headline excitement, focus your search on the 31 resilient stocks with low risk scores to see which businesses clear a tighter risk bar.
• When the goal is to uncover less crowded opportunities with strong underlying fundamentals, widen your funnel with the 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com